

Cijepljenje i COVID-19

Dubrovačka karantena

- Crna smrt u Dalmaciji: Split, Zadar, Šibenik, Dubrovnik
- 1377. prva karantena u svijetu: okolni otoci putnici i teret ostajali 40 dana prije ulaska u Grad
- 1627.g. izgrađeni Lazareti






Vakcinologija – E.Jenner


Mortalitet dojenčadi

Udio umrle djece u prvoj
godini života od svih
živorođenih


Difterija u Hrvatskoj 1945-2012.




Tetanus u Hrvatskoj 1946-2012.



Hripavac u Hrvatskoj 1949-2012.




Dječja paraliza u Hrvatskoj 1949-2012.








Mehanizmi djelovanja cjepiva




QA20.10 Finally, for each of the following statements, please indicate whether you believe them to be true or false. If you know, you can just indicate so.

The cure for cancer exists but is hidden from the public by commercial interests (%)




Rich countries have given out more boosters in three months than poor countries have given total doses all year...



...exacerbating stark inequalities in vaccine coverage

Share of population aged 12+ by vaccination status and country's income level



(a)

Death within 28 days of positive COVID-19 test by date of death between week 34 and week 37 2021	Total	Unlinked*	Not vaccinated	Received one dose (1-20 days before specimen date)	Received one dose, ≥21 days before specimen date	Second dose ≥14 days before specimen date	Rates among persons vaccinated with 2 doses (per 100,000)	Rates among persons not vaccinated (per 100,000)
Under 18	6	2	4	0	0	0	0.0	0.0
18 to 29	17	0	12	0	0	5	0.1	0.3
30 to 39	48	2	35	0	1	10	0.2	1.2
40 to 49	104	3	64	0	7	30	0.5	3.8
50 to 59	250	7	128	0	13	102	1.4	12.4
60 to 69	411	8	125	0	20	258	4.5	23.1
70 to 79	801	3	164	0	27	607	13.1	66.4
80+	1,521	8	198	1	42	1,272	49.5	156.5




**Table 1. Summary of evidence on vaccine effectiveness against different outcomes
Delta**

Outcome	Vaccine effectiveness*		
	Pfizer-BioNTech Cominarty	AstraZeneca Vaxzevria	Moderna Spikevax
Infection	75 to 85%	60 to 70%	
Symptomatic disease	80 to 90%	65 to 75%	90 to 99%
Hospitalisation	95 to 99%	90 to 99%	95 to 99%
Mortality	90 to 99%	90 to 95%	

High Confidence	Evidence from multiple studies which is consistent and comprehensive
Medium Confidence	Evidence is emerging from a limited number of studies or with a moderately level of uncertainty
Low Confidence	Little evidence is available at present and results are inconclusive

Razlika u broju umrlih u odnosu na petogodišnji prosjek 2015.-2019. (DZS)



Rješenje?



A do tada...

